|
Mechanismalpha-toxin inhibitors |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunomodulators |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价AR-301作为抗生素的联合治疗用于金黄色葡萄球菌性呼吸机相关性肺炎(VAP)治疗的有效性和安全性的III期临床研究
[Translation] Phase III clinical study evaluating the efficacy and safety of AR-301 as a combination therapy with antibiotics for the treatment of Staphylococcus aureus ventilator-associated pneumonia (VAP)
主要临床有效性目的:评价单独SOC治疗与SOC+AR-301联合治疗在第21天临床治愈率方面的差异。已与该领域的临床专家共同确定了严格的临床治愈标准;主要临床安全性目的:旨在评估AR-301在研究人群中的临床安全性和耐受性。
[Translation] Main clinical efficacy Objective: To evaluate the difference between SOC treatment alone and SOC + AR-301 combination treatment in clinical cure rate on day 21. Strict clinical cure criteria have been defined in collaboration with clinical experts in the field; Primary Clinical Safety Objective: To assess the clinical safety and tolerability of AR-301 in the study population.
100 Clinical Results associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.
100 Deals associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.